The U.S. government must prioritize Long COVID research like it did for AIDS and COVID vaccines
Source: "Long COVID is the next chronic crisis — and Washington must confront it now | Fox News." May 4, 2026. www.foxnews.com
The Gist
The author argues that Long COVID is a massive health crisis affecting 18 million Americans that costs hundreds of billions annually. Just like the government successfully tackled AIDS and rapidly developed COVID vaccines through focused investment, it should now prioritize Long COVID research to find treatments.
Conclusion
The Trump administration should direct aggressive federal investment and research efforts to develop effective treatments for Long COVID, treating it as a major chronic disease crisis requiring immediate government action
Premises
- Long COVID affects as many as 18 million Americans and causes severe, debilitating symptoms including cognitive dysfunction, extreme fatigue, and neurological problems
- There is currently no molecular diagnostic test, no clear understanding of the disease's pathogenesis, and no definitive therapy for Long COVID
- Long COVID costs the United States hundreds of billions of dollars annually in productivity losses and medical costs
- Historical precedent shows that aggressive government investment can transform fatal diseases into treatable conditions, as demonstrated with AIDS research over 30 years
- Operation Warp Speed successfully accelerated COVID vaccine development through focused government funding and industry engagement
- The NIH has failed to effectively invest necessary resources to solve Long COVID understanding or develop diagnostic tests
- Recent cuts to Long COVID research programs were premature and counterproductive, occurring just as they were yielding promising results
Assumptions
- Government-led research initiatives are more effective than private sector efforts alone for addressing major health crises
- Long COVID is a legitimate, serious medical condition comparable to AIDS in its impact and need for intervention
- The economic costs of Long COVID justify significant government spending on research
- Past success with AIDS research and COVID vaccine development can be replicated for Long COVID treatment development
- The current level of NIH investment in Long COVID research is insufficient relative to the problem's scope